🍽️ diphenidol hydrochloride,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Motion Sickness: Diphenidol hydrochloride is commonly used to prevent and treat motion sickness, which can occur during travel by car, boat, airplane, or other modes of transportation. By blocking signals in the brain that trigger nausea and vomiting in response to motion, diphenidol helps alleviate symptoms such as nausea, vomiting, dizziness, and sweating associated with motion sickness.

  2. Vertigo: Diphenidol hydrochloride may also be used in the management of vertigo, a sensation of spinning or dizziness that can be caused by various conditions affecting the inner ear or the balance centers of the brain. By exerting its anticholinergic effects, diphenidol can help reduce the severity and frequency of vertigo episodes and improve overall balance and stability.

  3. Nausea and Vomiting: In addition to motion sickness and vertigo, diphenidol hydrochloride may be prescribed to relieve nausea and vomiting associated with other conditions, such as gastrointestinal infections, chemotherapy, or postoperative recovery. It helps suppress the vomiting reflex and alleviate symptoms, making it easier for individuals to tolerate oral intake and maintain hydration.

  4. Postoperative Nausea and Vomiting (PONV): Diphenidol hydrochloride may be used as part of multimodal therapy to prevent or reduce postoperative nausea and vomiting in individuals undergoing surgery. By blocking signals in the brain that trigger nausea and vomiting in response to anesthesia or surgical stress, diphenidol can help improve postoperative comfort and recovery.

  5. Dizziness: Diphenidol hydrochloride's anticholinergic effects may also be beneficial in reducing dizziness associated with various medical conditions, such as labyrinthitis, Meniere's disease, or vestibular neuritis. It helps stabilize the vestibular system and reduce the perception of dizziness or imbalance.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of diphenidol hydrochloride,(prescription) On Probiotics

Rank Probiotic Impact
species Akkermansia muciniphila Reduces

Bacteria Impacted by diphenidol hydrochloride,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Bacteroides genus Decreases 👪 Source Study
Akkermansia genus Decreases 👪 Source Study
Fusobacterium genus Decreases 👪 Source Study Periodontal disease, Lemierre syndrome, skin ulcers
Ruminococcus genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Fusobacterium nucleatum species Decreases 📓 Source Study Infectious bacteria
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Ruminococcus bromii species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Fusobacterium nucleatum subsp. nucleatum subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of diphenidol hydrochloride,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.3 0.3
Allergic Rhinitis (Hay Fever) 0.3 0.3
Allergies 0.3 -0.3
Allergy to milk products 0.3 0.3
Alzheimer's disease 0.7 0.3 1.33
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.3 0.3 0
Ankylosing spondylitis 0.4 -0.4
Anorexia Nervosa 0.3 -0.3
Asthma 0.6 -0.6
Atherosclerosis 0.1 0.1 0
Atrial fibrillation 0.3 0.3 0
Autism 0.8 0.7 0.14
Barrett esophagus cancer 0.1 0.1
Bipolar Disorder 0.3 0.1 2
Brain Trauma 0.3 -0.3
Carcinoma 0.3 0.3 0
Celiac Disease 0.3 0.4 -0.33
Cerebral Palsy 0.1 0.3 -2
Chronic Fatigue Syndrome 0.8 0.3 1.67
Chronic Kidney Disease 0.3 0.3
Chronic Lyme 0.3 -0.3
Chronic Obstructive Pulmonary Disease (COPD) 0.1 0.1
Chronic Urticaria (Hives) 0.2 -0.2
Coagulation / Micro clot triggering bacteria 0.1 -0.1
Colorectal Cancer 0.6 0.6
Constipation 0.3 0.3
Coronary artery disease 0.1 0.1
COVID-19 0.8 0.9 -0.13
Crohn's Disease 0.8 0.5 0.6
cystic fibrosis 0.3 -0.3
deep vein thrombosis 0.1 -0.1
Depression 1 0.6 0.67
Endometriosis 0.3 0.1 2
Eosinophilic Esophagitis 0.1 0.1
Epilepsy 0.5 0.6 -0.2
Fibromyalgia 0.4 -0.4
Functional constipation / chronic idiopathic constipation 0.4 0.3 0.33
gallstone disease (gsd) 0.1 0.1 0
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.1 0.1
Generalized anxiety disorder 0.1 0.3 -2
Graves' disease 0.3 0.3
Halitosis 0.3 0.3
Hashimoto's thyroiditis 0.4 0.3 0.33
Hidradenitis Suppurativa 0.1 0.1
Histamine Issues 0.3 0.3
hypercholesterolemia (High Cholesterol) 0.2 -0.2
hyperglycemia 0.6 -0.6
Hyperlipidemia (High Blood Fats) 0.1 0.1
hypertension (High Blood Pressure 0.4 0.4 0
Hypoxia 0.4 0.4
IgA nephropathy (IgAN) 0.2 -0.2
Inflammatory Bowel Disease 0.3 0.7 -1.33
Insomnia 0.3 0.3 0
Intelligence 0.2 0.2
Intracranial aneurysms 0.3 0.3
Irritable Bowel Syndrome 0.5 0.7 -0.4
Liver Cirrhosis 0.5 0.4 0.25
Long COVID 0.5 0.5 0
Lung Cancer 0.3 -0.3
Mast Cell Issues / mastitis 0.1 -0.1
ME/CFS with IBS 0.3 -0.3
ME/CFS without IBS 0.1 0.3 -2
Metabolic Syndrome 0.5 0.9 -0.8
Mood Disorders 1.2 0.6 1
multiple chemical sensitivity [MCS] 0.1 0.1
Multiple Sclerosis 0.4 0.3 0.33
Multiple system atrophy (MSA) 0.3 0.1 2
neuropathic pain 0.4 -0.4
Neuropathy (all types) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.5 -0.5
Obesity 0.4 0.7 -0.75
obsessive-compulsive disorder 0.6 0.5 0.2
Osteoarthritis 0.3 0.1 2
Osteoporosis 0.3 0.5 -0.67
Parkinson's Disease 0.3 0.1 2
Polycystic ovary syndrome 0.4 0.2 1
primary biliary cholangitis 0.2 -0.2
Psoriasis 0.2 0.5 -1.5
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.6 0.3 1
Rosacea 0.1 0.1
Schizophrenia 0.7 0.1 6
scoliosis 0.1 -0.1
Sjögren syndrome 0.4 -0.4
Sleep Apnea 0.1 0.3 -2
Small Intestinal Bacterial Overgrowth (SIBO) 0.1 0.1
Stress / posttraumatic stress disorder 0.5 0.5 0
Systemic Lupus Erythematosus 0.3 0.1 2
Tic Disorder 0.1 0.1
Tourette syndrome 0.1 0.3 -2
Type 1 Diabetes 0.4 0 0
Type 2 Diabetes 0.5 0.9 -0.8
Ulcerative colitis 0.3 0.8 -1.67
Unhealthy Ageing 0.6 0.1 5

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant or equivalent EU laws. [34.239.170 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [34.239.170 ]